Xenpozyme Approved for Acid Sphingomyelinase Deficiency
The FDA has approved Xenpozyme (olipudase alfa-rpcp) for non-CNS manifestations of acid sphingomyelinase deficiency in adult and pediatric patients.
Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has approved Xenpozyme (olipudase alfa-rpcp) for non-CNS manifestations of acid sphingomyelinase deficiency in adult and pediatric patients.
Evolocumab significantly reduced LDL-C levels in adults with atherosclerotic cardiovascular disease (ASCVD) for over 8 years.
The FDA has approved Pemazyre (pemigatinib) for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Dapagliflozin significantly reduced the risk of CV death or worsening of HF in patients with HF and mildly reduced or preserved ejection fraction.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...